secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-09-23T23:59:59+00:00
Accession:  0001193125-22-250137
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Therapeutics CFO Carlos Campoy to depart Sept 30; Chris Ogden named principal financial officer
--------------------------------------------------------------------------------

- Carlos Campoy, SVP and CFO, expected to terminate employment effective Sept 30, 2022.
- Chris Ogden, SVP Finance and Accounting, assumes principal financial and principal accounting officer roles effective immediately.
- Ogden's biographical details incorporated by reference from April 2022 proxy statement.
- No family relationships or related party transactions between Ogden and the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522250137/0001193125-22-250137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522250137/d401274d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-250137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer